ストックスクリーナーアプリを入手
0.4349
9.40%
-0.0451
アフターアワーズ：
.43
-0.0049
-1.13%
前日終値:
$0.48
開ける：
$0.4888
24時間の取引高:
180.46K
Relative Volume:
0.17
時価総額：
$15.70M
収益：
-
当期純損益:
$-23.36M
株価収益率:
-0.5903
EPS:
-0.7368
ネットキャッシュフロー:
-
1週間 パフォーマンス:
-11.95%
1か月 パフォーマンス:
-12.34%
6か月 パフォーマンス:
-70.01%
1年 パフォーマンス:
-79.29%
1日の値動き範囲:
$0.4303
$0.4945
1週間の範囲:
$0.4303
$0.5098
52週間の値動き範囲:
$0.35
$4.90
Calidi Biotherapeutics Inc Stock (CLDI) Company Profile
名前
Calidi Biotherapeutics Inc
セクター
電話
(858) 794-9600
住所
4475 Executive Drive, Suite 200, San Diego
CLDI を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CLDI
Calidi Biotherapeutics Inc
|
0.4349 | 15.70M | 0 | -23.36M | 0 | -0.7368 |
|
VRTX
Vertex Pharmaceuticals Inc
|
450.03 | 129.44B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.52 | 61.42B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
615.11 | 38.44B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
269.81 | 33.29B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
241.75 | 26.95B | 3.81B | -644.79M | -669.77M | -6.24 |
Calidi Biotherapeutics Inc Stock (CLDI) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2023-11-22 | 開始されました | H.C. Wainwright | Buy |
| 2023-10-09 | 開始されました | Robert W. Baird | Outperform |
Calidi Biotherapeutics Inc (CLDI) 最新ニュース
Geode Capital Management LLC Buys 120,406 Shares of Calidi Biotherapeutics, Inc. (NYSE:CLDI) - Defense World
Join Calidi Biotherapeutics’ Exclusive Live Investor Webinar and Q&A Session on February 5 - The Globe and Mail
Calidi Biotherapeutics (NYSE:CLDI) Stock Price Down 0.3% – Time to Sell? - Defense World
Investor’s Delight: Calidi Biotherapeutics Inc (CLDI) Closes Weak at 0.65, Down -6.53 - DWinneX
Calidi (CLDI) Advances Cancer Treatment with IL15 Superagonist a - GuruFocus
Calidi Biotherapeutics Announces IL15 Superagonist as First - GlobeNewswire
Revolutionary Cancer Treatment Platform Shows Complete Tumor Elimination: First Systemic Delivery Success - Stock Titan
Calidi Biotherapeutics (CLDI) Awards Stock Option to New CEO Eri - GuruFocus
Calidi Biotherapeutics Reports Inducement Grant Under NYSE American LLC Company Guide Section 711 - The Manila Times
Calidi Bio's Strategic Move: New CEO Secures 726K Share Options with 4-Year Performance Lock - Stock Titan
Calidi Biotherapeutics appoints new CEO By Investing.com - Investing.com South Africa
Zealand names former Lilly exec Singh as CSO - biocentury.com
Calidi Biotherapeutics appoints new CEO - Investing.com
Calidi (CLDI) Appoints New CEO as Eric Poma Assumes Leadership | - GuruFocus
Calidi Biotherapeutics Appoints New CEO Eric Poma - TipRanks
Calidi Biotherapeutics Announces Chief Executive Officer Transition And Appointment Of Eric Poma, Ph.D. As CEO And Director - TradingView
Calidi Biotherapeutics Announces Chief Executive Officer - GlobeNewswire
New Calidi Bio CEO Brings $400M Funding Success Record: Strategic Shift for Cancer Treatment Pioneer - Stock Titan
Calidi Biotherapeutics Announces Appointment of Guy Travis Clifton, MD as Chief Medical Officer, Consultant and Advisor - The Globe and Mail
Join Calidi Biotherapeutics' Exclusive Live Investor Webinar and Q&A Session on April 24 - The Manila Times
Join Calidi Biotherapeutics’ Exclusive Live Investor Webinar and Q&A Session on April 24 - GlobeNewswire
Cancer Breakthrough Alert: Top Oncologist Reveals New FDA-Cleared Stem Cell Therapy Development - Stock Titan
Calidi Biotherapeutics Announces FDA Clearance of IND Application for CLD-201 in Solid Tumors - The Manila Times
FDA Green Lights Revolutionary Cancer Treatment: Stem Cells Combined With Virus to Fight Multiple Tumors - Stock Titan
Calidi Biotherapeutics Announces Appointment of Guy Travis - GlobeNewswire
Cancer Drug Developer Calidi Bio Strengthens Leadership: Renowned Oncologist Takes CMO Role - Stock Titan
Calidi Biotherapeutics Appoints New Chief Medical Officer - TipRanks
CLDI stock touches 52-week low at $0.42 amid market challenges By Investing.com - Investing.com South Africa
CLDI stock touches 52-week low at $0.42 amid market challenges - Investing.com India
Press Release Distribution & PR Platform - ACCESS Newswire
ASP Isotopes and Calidi Biotherapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - ACCESS Newswire
HighTower Advisors LLC Makes New Investment in Calidi Biotherapeutics, Inc. (NYSE:CLDI) - Defense World
Calidi Biotherapeutics Announces Closing of $3.9 Million Registered Direct Offering and Concurrent Private Placement - GlobeNewswire
CLDI stock plunges to 52-week low, hitting $0.57 amid market challenges By Investing.com - Investing.com South Africa
Calidi Biotherapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Operational Highlights - The Manila Times
Calidi Bio Raises Fresh $3.9M Capital to Advance Clinical Programs - Stock Titan
Calidi Biotherapeutics Cuts Losses by 50% While Expanding Cancer Gene Therapy Trials - Stock Titan
CLDI stock plunges to 52-week low, hitting $0.57 amid market challenges - Investing.com India
Virtu Financial LLC Buys Shares of 73,448 Calidi Biotherapeutics, Inc. (NYSE:CLDI) - Defense World
Calidi Biotherapeutics sinks after pricing $3.9M registered direct offering - MSN
Calidi prices 3.33M shares at 65c in registered direct offering - TipRanks
Calidi Biotherapeutics Announces Pricing of $3.9 Million Registered Direct Offering and Concurrent Private Placement - GlobeNewswire
Calidi Bio Secures Strategic $3.9M Investment to Accelerate Cancer Immunotherapy Pipeline - Stock Titan
Calidi Biotherapeutics Provides Update On Phase 1 Trial Of CLD-101 For Recurrent Glioma - Nasdaq
Calidi Biotherapeutics and City of Hope Provide Update on a - GlobeNewswire
Calidi Biotherapeutics And City Of Hope Provide Update On A Phase 1 Clinical Trial With CLD-101 Virotherapy In Patients With Recurrent High-Grade Glioma - MarketScreener
Breakthrough Brain Cancer Treatment Advances: 14 Patients Successfully Treated in Groundbreaking Trial - Stock Titan
CLDI stock touches 52-week low at $0.73 amid market challenges - MSN
Nexalin Technology and Calidi Biotherapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - Weatherford Democrat
IBN Coverage: Calidi Biotherapeutics (NYSE American: CLDI) Reports Promising Preclinical Results for RTNova Virotherapy Platform - Yahoo Finance
Calidi’s Rtnova platform delivers transient gene therapy payloads to tumors - BioWorld Online
Calidi Biotherapeutics Inc (CLDI) 財務データ
収益
当期純利益
現金流量
EPS
5.24%
大文字化:
|
ボリューム (24 時間):